TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis
Brief Summary: The aim of our study is to ascertain whether chest physiotherapy + pulmonary rehabilitation is more efficacious than chest physiotherapy alone. The outcomes that will be used to assess effectiveness are relevant in terms of the direct benefit on the patient's health related quality of life.

PLANNED STUDY: This randomized study will compare 8 weeks chest physiotherapy with 8 weeks chest physiotherapy plus pulmonary rehabilitation.


Options:
A: Arm Label: Ciprofloxacin DPI 28 Days on/off (Cipro 28); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Ciprofloxacin DPI 14 Days on/off (Cipro 14); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin DPI (BAYQ3939) | Arm Label: Placebo 28 Days on/off (Placebo 28); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo 14 Days on/off (Placebo 14); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin DPI (BAYQ3939); Assigned to Arm(s): Ciprofloxacin DPI 14 Days on/off (Cipro 14), Ciprofloxacin DPI 28 Days on/off (Cipro 28) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo 14 Days on/off (Placebo 14), Placebo 28 Days on/off (Placebo 28)
B: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe COPD patients.


Options:
A: Arm Label: Aclidinium bromide 100 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 100 μg bid | Arm Label: Aclidininum bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidininum bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Formoterol 12 μg bid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol 12 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 100 μg bid; Assigned to Arm(s): Aclidinium bromide 100 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidininum bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidininum bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Formoterol 12 μg bid; Assigned to Arm(s): Formoterol 12 μg bid
B: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
D: Arm Label: Aclidinium; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe COPD patients.


Options:
A: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tiotropium; Type: EXPERIMENTAL; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Brief Summary: The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke. 1070 patients were randomized in this trial in 2 parallel groups, one receiving Cerebrolysin, the control group receiving Placebo. Study drug will be given once daily by intravenous infusion for 10 consecutive days. Acetylsalicylic acid will be given orally, once daily throughout the study duration of 90 days as basic treatment. The clinical observation period for each patient will be 3 months and will include six clinical evaluation visits at Baseline (day 1) and on study days 2, 5, 10, 30 and 90.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
C: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Brief Summary: The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke. 1070 patients were randomized in this trial in 2 parallel groups, one receiving Cerebrolysin, the control group receiving Placebo. Study drug will be given once daily by intravenous infusion for 10 consecutive days. Acetylsalicylic acid will be given orally, once daily throughout the study duration of 90 days as basic treatment. The clinical observation period for each patient will be 3 months and will include six clinical evaluation visits at Baseline (day 1) and on study days 2, 5, 10, 30 and 90.


Options:
A: Arm Label: Cerebrolysin + donepezil; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + donepezil | Arm Label: Cerebrolysin + placebo; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + placebo | Arm Label: Donepezil + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil + placebo | Intervention Type: DRUG; Name: Cerebrolysin + donepezil; Assigned to Arm(s): Cerebrolysin + donepezil | Intervention Type: DRUG; Name: Cerebrolysin + placebo; Assigned to Arm(s): Cerebrolysin + placebo | Intervention Type: DRUG; Name: Donepezil + placebo; Assigned to Arm(s): Donepezil + placebo
B: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
D: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Brief Summary: The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke. 1070 patients were randomized in this trial in 2 parallel groups, one receiving Cerebrolysin, the control group receiving Placebo. Study drug will be given once daily by intravenous infusion for 10 consecutive days. Acetylsalicylic acid will be given orally, once daily throughout the study duration of 90 days as basic treatment. The clinical observation period for each patient will be 3 months and will include six clinical evaluation visits at Baseline (day 1) and on study days 2, 5, 10, 30 and 90.


Options:
A: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
B: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
Brief Summary: The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke. 1070 patients were randomized in this trial in 2 parallel groups, one receiving Cerebrolysin, the control group receiving Placebo. Study drug will be given once daily by intravenous infusion for 10 consecutive days. Acetylsalicylic acid will be given orally, once daily throughout the study duration of 90 days as basic treatment. The clinical observation period for each patient will be 3 months and will include six clinical evaluation visits at Baseline (day 1) and on study days 2, 5, 10, 30 and 90.


Options:
A: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
B: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
C: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Macronutrient Relations on Body Weight, Body Composition, and Cardiovascular Risk Markers in Overweight Patients Attending a Telemedically Guided Weight Loss Program
Brief Summary: The burden of overweight and obesity has dramatically increased during the last decades. High carbohydrate intake, particularly refined carbohydrates, probably increase the risk of obesity, type 2 diabetes, and metabolic syndrome. There is evidence that energy-restricted low-carbohydrate diets show greater weight loss and better improvement of cardiovascular risk markers compared to energy-restricted low-fat diets. Beside macronutrient relations, efficacy of weight loss programs depends on care and control. The investigators aim to investigate whether or not a carbohydrate-restricted telemedically guided weight loss program results in a more pronounced weight loss and influences metabolic risk markers more beneficial than a fat-restricted diet.


Options:
A: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle counseling | Arm Label: Cognitive Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Training | Intervention Type: BEHAVIORAL; Name: lifestyle counseling; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training
B: Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet
C: Arm Label: 1- physical activity tailored; Type: EXPERIMENTAL; Interventions: Behavioral: physical activity tailored | Arm Label: 2 - physical activity standard; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: physical activity standard | Intervention Type: BEHAVIORAL; Name: physical activity tailored; Assigned to Arm(s): 1- physical activity tailored | Intervention Type: BEHAVIORAL; Name: physical activity standard; Assigned to Arm(s): 2 - physical activity standard
D: Arm Label: Control-group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control-group | Arm Label: Intervention-group; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention-group | Intervention Type: BEHAVIORAL; Name: Intervention-group; Assigned to Arm(s): Intervention-group | Intervention Type: BEHAVIORAL; Name: Control-group; Assigned to Arm(s): Control-group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Macronutrient Relations on Body Weight, Body Composition, and Cardiovascular Risk Markers in Overweight Patients Attending a Telemedically Guided Weight Loss Program
Brief Summary: The burden of overweight and obesity has dramatically increased during the last decades. High carbohydrate intake, particularly refined carbohydrates, probably increase the risk of obesity, type 2 diabetes, and metabolic syndrome. There is evidence that energy-restricted low-carbohydrate diets show greater weight loss and better improvement of cardiovascular risk markers compared to energy-restricted low-fat diets. Beside macronutrient relations, efficacy of weight loss programs depends on care and control. The investigators aim to investigate whether or not a carbohydrate-restricted telemedically guided weight loss program results in a more pronounced weight loss and influences metabolic risk markers more beneficial than a fat-restricted diet.


Options:
A: Arm Label: energy-restricted, CHO-restricted diet; Type: EXPERIMENTAL; Interventions: Other: energy-restricted, CHO-restricted diet | Arm Label: energy-restricted, CHO-rich diet; Type: ACTIVE_COMPARATOR; Interventions: Other: energy-restricted, CHO-rich diet | Intervention Type: OTHER; Name: energy-restricted, CHO-restricted diet; Assigned to Arm(s): energy-restricted, CHO-restricted diet | Intervention Type: OTHER; Name: energy-restricted, CHO-rich diet; Assigned to Arm(s): energy-restricted, CHO-rich diet
B: Arm Label: Weight loss high protein; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Protein supplementation, Behavioral: Diet counseling and group education lessons | Arm Label: Weight loss control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet counseling and group education lessons | Intervention Type: DIETARY_SUPPLEMENT; Name: Protein supplementation; Assigned to Arm(s): Weight loss high protein | Intervention Type: BEHAVIORAL; Name: Diet counseling and group education lessons; Assigned to Arm(s): Weight loss control, Weight loss high protein
C: Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A
D: Arm Label: Vegan Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Arm Label: Omnivorous (Omni) Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Intervention Type: BEHAVIORAL; Name: Dietary Intervention Meetings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Podcasts/Mailings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet

Answer: A